SG10201601719RA - Anti-LAG-3 Antibodies - Google Patents
Anti-LAG-3 AntibodiesInfo
- Publication number
- SG10201601719RA SG10201601719RA SG10201601719RA SG10201601719RA SG10201601719RA SG 10201601719R A SG10201601719R A SG 10201601719RA SG 10201601719R A SG10201601719R A SG 10201601719RA SG 10201601719R A SG10201601719R A SG 10201601719RA SG 10201601719R A SG10201601719R A SG 10201601719RA
- Authority
- SG
- Singapore
- Prior art keywords
- lag
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10201601719RA SG10201601719RA (en) | 2016-03-04 | 2016-03-04 | Anti-LAG-3 Antibodies |
| CN201780015245.3A CN109219619A (en) | 2016-03-04 | 2017-03-03 | anti-LAG-3 antibody |
| KR1020187028534A KR20180114218A (en) | 2016-03-04 | 2017-03-03 | Anti-LAG-3 antibody |
| TW106107003A TW201734042A (en) | 2016-03-04 | 2017-03-03 | Anti-LAG-3 antibodies |
| AU2017226965A AU2017226965A1 (en) | 2016-03-04 | 2017-03-03 | Anti-LAG-3antibodies |
| JP2018546454A JP2019517773A (en) | 2016-03-04 | 2017-03-03 | Anti-LAG-3 antibody |
| PCT/EP2017/055060 WO2017149143A1 (en) | 2016-03-04 | 2017-03-03 | Anti-lag-3 antibodies |
| EP17710682.0A EP3423492A1 (en) | 2016-03-04 | 2017-03-03 | Anti-lag-3 antibodies |
| CA3015938A CA3015938A1 (en) | 2016-03-04 | 2017-03-03 | Anti-lag-3 antibodies |
| US16/079,947 US20190040136A1 (en) | 2016-03-04 | 2017-03-03 | Anti-lag-3 antibodies |
| SG11201807252QA SG11201807252QA (en) | 2016-03-04 | 2017-03-03 | Anti-lag-3 antibodies |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10201601719RA SG10201601719RA (en) | 2016-03-04 | 2016-03-04 | Anti-LAG-3 Antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201601719RA true SG10201601719RA (en) | 2017-10-30 |
Family
ID=58277259
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201601719RA SG10201601719RA (en) | 2016-03-04 | 2016-03-04 | Anti-LAG-3 Antibodies |
| SG11201807252QA SG11201807252QA (en) | 2016-03-04 | 2017-03-03 | Anti-lag-3 antibodies |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201807252QA SG11201807252QA (en) | 2016-03-04 | 2017-03-03 | Anti-lag-3 antibodies |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20190040136A1 (en) |
| EP (1) | EP3423492A1 (en) |
| JP (1) | JP2019517773A (en) |
| KR (1) | KR20180114218A (en) |
| CN (1) | CN109219619A (en) |
| AU (1) | AU2017226965A1 (en) |
| CA (1) | CA3015938A1 (en) |
| SG (2) | SG10201601719RA (en) |
| TW (1) | TW201734042A (en) |
| WO (1) | WO2017149143A1 (en) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI756187B (en) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | Anti-lag3 antibodies and uses thereof |
| JP7066696B2 (en) | 2016-10-11 | 2022-05-13 | アジェナス インコーポレイテッド | Anti-LAG-3 antibody and its usage |
| MA46814B2 (en) | 2017-02-10 | 2022-09-30 | Regeneron Pharma | Radiolabeled anti-lag3 antibodies for immuno-pet imaging |
| BR112019018759A2 (en) | 2017-05-30 | 2020-05-05 | Bristol-Myers Squibb Company | compositions comprising a combination of an anti-lag-3 antibody, an inhibitor of the pd-1 pathway, and an immunotherapeutic agent |
| DK3631454T3 (en) | 2017-05-30 | 2023-12-04 | Bristol Myers Squibb Co | TREATMENT OF LAYER-3 POSITIVE TUMORS |
| CA3065304A1 (en) | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody |
| CN111954680B (en) | 2017-11-10 | 2024-03-15 | 新加坡科技研究局 | IL2 Rbeta/common gamma chain antibodies |
| WO2019179365A1 (en) * | 2018-03-20 | 2019-09-26 | WuXi Biologics Ireland Limited | Novel anti-lag-3 antibody polypeptide |
| CN110343178B (en) | 2018-04-03 | 2022-07-22 | 上海开拓者生物医药有限公司 | Anti-human LAG-3 monoclonal antibody and application thereof |
| CA3100349A1 (en) * | 2018-05-17 | 2019-11-21 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor inhibition by phosphatase recruitment |
| EP3826660A1 (en) | 2018-07-26 | 2021-06-02 | Bristol-Myers Squibb Company | Lag-3 combination therapy for the treatment of cancer |
| DK3866850T3 (en) | 2018-10-19 | 2024-10-14 | Bristol Myers Squibb Co | COMBINATION THERAPY AGAINST MELANOMA |
| TW202031683A (en) | 2018-11-09 | 2020-09-01 | 新加坡商優其洛伊生物私人有限公司 | Il2rbeta/common gamma chain antibodies |
| TW202039557A (en) | 2018-11-09 | 2020-11-01 | 新加坡商優其洛伊生物私人有限公司 | Il2rbeta/common gamma chain antibodies |
| US12187800B2 (en) * | 2018-11-22 | 2025-01-07 | Suzhou Kanova Biopharmaceutical Co., Ltd. | Anti-B7-H3 antibody |
| GB201906118D0 (en) * | 2019-05-01 | 2019-06-12 | Immutep S A | Anti-LAG-3 binding molecules |
| EP3976832A1 (en) | 2019-05-30 | 2022-04-06 | Bristol-Myers Squibb Company | Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy |
| JP2022534967A (en) | 2019-05-30 | 2022-08-04 | ブリストル－マイヤーズ スクイブ カンパニー | Multiple tumor gene signatures and their uses |
| CN114174537A (en) | 2019-05-30 | 2022-03-11 | 百时美施贵宝公司 | Cell localization features and combination therapies |
| IL267614A (en) * | 2019-06-24 | 2019-09-26 | Lotem Michal | Nucleic acid agents modulating slamf6 isoforms |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| BR112022004316A2 (en) | 2019-09-22 | 2022-06-21 | Bristol Myers Squibb Co | Quantitative spatial characterization for lag-3 antagonist therapy |
| WO2021092221A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
| WO2021092220A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
| BR112022008191A2 (en) | 2019-11-08 | 2022-07-12 | Bristol Myers Squibb Co | LAG-3 ANTAGONIST THERAPY FOR MELANOMA |
| KR20220139915A (en) | 2020-02-06 | 2022-10-17 | 브리스톨-마이어스 스큅 컴퍼니 | IL-10 and its uses |
| KR102555328B1 (en) * | 2020-02-06 | 2023-07-17 | 아주대학교산학협력단 | T cell receptor-like antibody to CMV pp65 peptide presented by HLA-A*02 and uses thereof |
| MX2023000197A (en) | 2020-07-07 | 2023-02-22 | BioNTech SE | THERAPEUTIC RNA FOR HPV POSITIVE CANCER. |
| US20230265188A1 (en) | 2020-08-28 | 2023-08-24 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hepatocellular carcinoma |
| US20230303700A1 (en) | 2020-08-31 | 2023-09-28 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
| WO2022087402A1 (en) | 2020-10-23 | 2022-04-28 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for lung cancer |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| CN114621345B (en) * | 2020-12-10 | 2022-11-29 | 北京东方百泰生物科技股份有限公司 | anti-LAG-3 monoclonal antibody, antigen binding fragment thereof and application thereof |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| TW202245808A (en) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | Therapeutic rna for treating cancer |
| JP2024501029A (en) | 2020-12-28 | 2024-01-10 | ブリストル－マイヤーズ スクイブ カンパニー | Subcutaneous administration of PD1/PD-L1 antibodies |
| ES3023507T3 (en) | 2020-12-28 | 2025-06-02 | Bristol Myers Squibb Co | Antibody compositions and methods of use thereof |
| WO2022165214A1 (en) | 2021-01-29 | 2022-08-04 | Board Of Regents, The University Of Texas System | Methods of treating cancer with kinase inhibitors |
| AU2022246593A1 (en) | 2021-03-29 | 2023-10-12 | Juno Therapeutics, Inc. | Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy |
| US20240279225A1 (en) | 2021-04-08 | 2024-08-22 | Board Of Regents, The University Of Texas System | Compounds and methods for theranostic targeting of parp activity |
| WO2022240741A1 (en) | 2021-05-12 | 2022-11-17 | Dana-Farber Cancer Institute, Inc. | Lag3 and gal3 inhibitory agents, xbp1, cs1, and cd138 peptides, and methods of use thereof |
| MX2024000674A (en) | 2021-07-13 | 2024-02-07 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer. |
| TW202333802A (en) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | Therapeutic rna for lung cancer |
| WO2023077090A1 (en) | 2021-10-29 | 2023-05-04 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hematological cancer |
| EP4469477A1 (en) | 2022-01-26 | 2024-12-04 | Bristol-Myers Squibb Company | Combination therapy for hepatocellular carcinoma |
| JP2025507694A (en) | 2022-02-25 | 2025-03-21 | ブリストル－マイヤーズ スクイブ カンパニー | Combination Therapy for Colorectal Cancer |
| WO2023168404A1 (en) | 2022-03-04 | 2023-09-07 | Bristol-Myers Squibb Company | Methods of treating a tumor |
| US20250179170A1 (en) | 2022-03-08 | 2025-06-05 | Alentis Therapeutics Ag | Use of anti-claudin-1 antibodies to increase t cell availability |
| EP4493575A1 (en) | 2022-03-18 | 2025-01-22 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
| JP2025518785A (en) | 2022-06-02 | 2025-06-19 | ブリストル－マイヤーズ スクイブ カンパニー | Antibody compositions and methods of use thereof |
| CN115651082A (en) * | 2022-11-04 | 2023-01-31 | 西北农林科技大学 | Preparation method and application of pig LAG3 monoclonal antibody |
| WO2024116140A1 (en) | 2022-12-01 | 2024-06-06 | Medimmune Limited | Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies |
| WO2024126457A1 (en) | 2022-12-14 | 2024-06-20 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
| IL321575A (en) | 2022-12-21 | 2025-08-01 | Bristol Myers Squibb Co | Combination therapy for lung cancer |
| US20240299601A1 (en) | 2023-02-17 | 2024-09-12 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-lag3 antibodies for immuno-pet imaging |
| WO2024196952A1 (en) | 2023-03-20 | 2024-09-26 | Bristol-Myers Squibb Company | Tumor subtype assessment for cancer therapy |
| WO2025038763A1 (en) | 2023-08-15 | 2025-02-20 | Bristol-Myers Squibb Company | Ceramic hydroxyapatite chromatography flow through method |
| WO2025096478A1 (en) | 2023-10-30 | 2025-05-08 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation comprising fianlimab |
| WO2025121445A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| US20250269052A1 (en) | 2024-02-27 | 2025-08-28 | Bristol-Myers Squibb Company | Anti-ceacam5 antibody drug conjugates |
| WO2025184208A1 (en) | 2024-02-27 | 2025-09-04 | Bristol-Myers Squibb Company | Anti-ceacam5 antibodies and uses thereof |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0615451T3 (en) | 1992-05-26 | 2006-04-24 | Immunex Corp | Hitherto unknown cytokine that binds to CD30 |
| ITRM20010408A1 (en) | 2001-07-10 | 2003-01-10 | Univ Napoli Federico Ii | CYTOTOXIC HUMAN MINI-ANTIBODY FOR CANCER CELLS THAT EXPRESS THE ERBB2 RECEPTOR. |
| KR100668538B1 (en) | 2002-01-09 | 2007-01-16 | 메다렉스, 인코포레이티드 | Human monoclonal antibodies against CD300 |
| MXPA06008700A (en) | 2004-02-06 | 2007-01-19 | Morphosys Ag | Anti-cd38 human antibodies and uses therefor. |
| SI2287195T1 (en) | 2004-07-01 | 2019-08-30 | Novo Nordisk A/S | Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy |
| SG10201912554TA (en) | 2005-03-23 | 2020-02-27 | Genmab As | Antibodies against cd38 for treatment of multiple myeloma |
| CA3151350A1 (en) | 2005-05-09 | 2006-11-16 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| TWI461436B (en) | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | Human CD134 (OX40) human monoclonal antibody and method of making and using same |
| BRPI0714728A2 (en) | 2006-08-04 | 2013-05-14 | Astrazeneca Ab | targeted binding agent, antibody, composition, isolated cell line isolated nucleic acid molecule, vector, host cell, methods for making a targeted binding agent, for isolating an antibody or antigen binding portion thereof, for making an antibody human monoclonal construct, to treat, prevent or alleviate the symptoms of a disorder, to inhibit the proliferation of a cancer cell, to inhibit an erbb2 activity in an erbb2 expressing cell, and to modulate an erbb2 activity in an erbb2 expressing cell. and non-human transgenic animal or transgenic plant |
| CA2669520C (en) | 2006-11-13 | 2016-07-26 | The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center | Methods of treating cancer using sirna molecules directed against cd24 |
| HRP20131113T1 (en) | 2007-02-16 | 2014-01-17 | Merrimack Pharmaceuticals, Inc. | Antibodies against erbb3 and uses thereof |
| EP1987839A1 (en) * | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| US9244059B2 (en) * | 2007-04-30 | 2016-01-26 | Immutep Parc Club Orsay | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| KR20100093578A (en) | 2007-11-30 | 2010-08-25 | 브리스톨-마이어스 스큅 컴퍼니 | Anti-b7h4 monoclonal antibody-drug conjugate and methods of use |
| AR072999A1 (en) * | 2008-08-11 | 2010-10-06 | Medarex Inc | HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE |
| PT4209510T (en) | 2008-12-09 | 2024-04-02 | Hoffmann La Roche | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| EP2478110B1 (en) | 2009-09-16 | 2016-01-06 | Immunomedics, Inc. | Class i anti-cea antibodies and uses thereof |
| BR122016002916B8 (en) | 2010-03-04 | 2021-05-25 | Macrogenics Inc | diabody, nucleic acid molecule, pharmaceutical composition and uses of diabody |
| CN103068850A (en) | 2010-05-26 | 2013-04-24 | 明尼苏达大学评议会 | Single -chain variable fragment anti-cd133 antibodies and uses thereof |
| PE20131403A1 (en) | 2010-08-23 | 2014-01-10 | Univ Texas | ANTI-OX40 ANTIBODIES AND METHODS OF USING THEM |
| MX344773B (en) | 2011-04-25 | 2017-01-06 | Daiichi Sankyo Co Ltd | Anti-b7-h3 antibody. |
| GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
| ES2694153T3 (en) | 2011-09-30 | 2018-12-18 | Regeneron Pharmaceuticals, Inc. | Antibodies anti-ErbB3 and uses thereof |
| WO2013067492A1 (en) | 2011-11-03 | 2013-05-10 | The Trustees Of The University Of Pennsylvania | Isolated b7-h4 specific compositions and methods of use thereof |
| WO2014039983A1 (en) | 2012-09-07 | 2014-03-13 | The Trustees Of Dartmouth College | Vista modulators for diagnosis and treatment of cancer |
| WO2014066532A1 (en) | 2012-10-23 | 2014-05-01 | Bristol-Myers Squibb Company | Combination of anti-kir and anti-ctla-4 antibodies to treat cancer |
| CA2894689A1 (en) | 2012-12-19 | 2014-06-26 | Amplimmune, Inc. | Anti-human b7-h4 antibodies and their uses |
| US9573988B2 (en) | 2013-02-20 | 2017-02-21 | Novartis Ag | Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells |
| MA38498B1 (en) * | 2013-03-15 | 2018-11-30 | Glaxosmithkline Ip Dev Ltd | Anti-lag-3 binding proteins |
| WO2014160627A1 (en) | 2013-03-25 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-cd276 polypeptides, proteins, and chimeric antigen receptors |
| BR122023024195A2 (en) | 2013-09-20 | 2023-12-26 | Bristol-Myers Squibb Company | USES OF ANTI-LAG-3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES |
| SG10201805933TA (en) | 2013-12-24 | 2018-08-30 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments |
-
2016
- 2016-03-04 SG SG10201601719RA patent/SG10201601719RA/en unknown
-
2017
- 2017-03-03 US US16/079,947 patent/US20190040136A1/en not_active Abandoned
- 2017-03-03 CA CA3015938A patent/CA3015938A1/en not_active Abandoned
- 2017-03-03 CN CN201780015245.3A patent/CN109219619A/en active Pending
- 2017-03-03 TW TW106107003A patent/TW201734042A/en unknown
- 2017-03-03 KR KR1020187028534A patent/KR20180114218A/en not_active Withdrawn
- 2017-03-03 JP JP2018546454A patent/JP2019517773A/en active Pending
- 2017-03-03 WO PCT/EP2017/055060 patent/WO2017149143A1/en not_active Ceased
- 2017-03-03 AU AU2017226965A patent/AU2017226965A1/en not_active Abandoned
- 2017-03-03 EP EP17710682.0A patent/EP3423492A1/en not_active Withdrawn
- 2017-03-03 SG SG11201807252QA patent/SG11201807252QA/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201734042A (en) | 2017-10-01 |
| SG11201807252QA (en) | 2018-09-27 |
| CN109219619A (en) | 2019-01-15 |
| JP2019517773A (en) | 2019-06-27 |
| US20190040136A1 (en) | 2019-02-07 |
| WO2017149143A1 (en) | 2017-09-08 |
| EP3423492A1 (en) | 2019-01-09 |
| CA3015938A1 (en) | 2017-09-08 |
| KR20180114218A (en) | 2018-10-17 |
| AU2017226965A1 (en) | 2018-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201900373B (en) | Anti-tim-3 antibodies | |
| IL259048A (en) | Anti-ror1 antibodies | |
| SG10201601719RA (en) | Anti-LAG-3 Antibodies | |
| GB201601073D0 (en) | Antibodies | |
| SG10201913864RA (en) | Anti-LAG-3 Antibodies | |
| GB201621439D0 (en) | IL-11Ra Antibodies | |
| IL253633A0 (en) | Anti-transthyretin antibodies | |
| GB201521391D0 (en) | Antibodies | |
| GB201521393D0 (en) | Antibodies | |
| GB201610044D0 (en) | Antibodies | |
| GB201521382D0 (en) | Antibodies | |
| PL3250593T3 (en) | Anti-transthyretin antibodies | |
| IL255323A0 (en) | Anti-fcrn antibodies | |
| GB201616699D0 (en) | Antibodies | |
| ZA201808317B (en) | Anti-tnfrsf25 antibodies | |
| GB201603291D0 (en) | Antibodies | |
| PT3484921T (en) | Anti-il-22r antibodies | |
| IL260083A (en) | Anti-myl9 antibody | |
| GB201509907D0 (en) | Antibodies | |
| GB201522394D0 (en) | Antibodies | |
| GB201503438D0 (en) | Antibodies | |
| IL284022A (en) | Anti-transthyretin antibodies | |
| GB201622197D0 (en) | Antibodies | |
| GB201620414D0 (en) | Antibodies | |
| GB201615224D0 (en) | Antibodies |